Çѵ¶ MSL / MI / BD(»ç¾÷°³¹ß) / ÀλçÃѹ« / ´ç´¢¸¶ÄÉÆà / Àü½Ã±âȹ ä¿ë

¸ðÁýºÎ¹®

MSL(Medical Science Liaison)
°ø°í¸¶°¨ÀÏ
  • 2024/05/06
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • ½ÅÀÔ/°æ·Â
Á÷¹«»ó¼¼ MSLÀº field-based medical force·Î¼­ ¾Æ·¡¿Í °°Àº ¿ªÇÒ°ú Ã¥ÀÓÀÌ ÀÖ½À´Ï´Ù.
  • Medical Thought Leader¿¡°Ô Á¦Ç°ÀÇ ¿Ã¹Ù¸¥ ÀÇÇÐÀû °¡Ä¡(value)¸¦ °úÇÐÀû ±Ù°Å¸¦ ¹ÙÅÁÀ¸·Î °´°ü/±ÕÇüÀÖ°Ô Àü´Þ, medical insightÀÇ ¼öÁý/°øÀ¯, ÀÇÇÐÀû Àü·« ¼ö¸³/½ÇÇà
  • Á¦Ç°ÀÇ Life cycle¿¡ °ÉÃÄ Scientific program(½ÉÆ÷Áö¾ö, ÀÚ¹®È¸ÀÇ)ÀÇ ±âȹ ¹× ½ÇÇà
  • Á¦Ç° ¶Ç´Â Áúȯ°ú °ü·ÃµÈ ÀÓ»ó ¿¬±¸¸¦ °ü·Ã ±ÔÁ¤¿¡ µû¶ó È¿À²ÀûÀ¸·Î °ü¸®ÇÏ°í Áö¿ø
  • °ü·Ã Á¦Ç° ¹× Áúȯ¿¡ ´ëÇÑ ÀÇÇÐ ±³À°À» °èȹÇÏ°í ½ÃÇà
Áö¿øÀÚ°Ý
  • ¾à»ç ȤÀº À¯°üÇаú (»ý¹°ÇÐ, »ý¸í°úÇÐ µî ÀÚ¿¬°úÇÐ ÇÐÀ§) Á¹¾÷ÀÚ
  • Á¦¾àȸ»ç ¶Ç´Â °ü·Ã ȸ»ç¿¡¼­ MSL °æ·Â ¿ì´ë
  • ÀÓ»ó½ÃÇè °á°ú ¹× ¿¬±¸ ³í¹®¿¡ ´ëÇÑ ÀÌÇصµ
  • Learning agility (»õ·Î¿î Áúȯ ¹× Á¦Ç°¿¡ ´ëÇÑ ÇнÀ ¼ø¹ß·Â)
  • Communication skill; °í°´°úÀÇ ÀÇ»ç¼ÒÅë ´É·Â ¹× °í°´ÁöÇâÀûÀÎ ¼ºÇâ
Business Development ÆÀ¿ø
°ø°í¸¶°¨ÀÏ
  • 2024/05/06
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • ½ÅÀÔ ¹× °æ·Â
Á÷¹«»ó¼¼ Lisensing-In
  • ȸ»ç Àü·«¿¡ ºÎÇÕÇÏ´Â Æ÷Æ®Æú¸®¿À¿¡ µû¶ó Á¦Ç° ¹× »ç¾÷ ±âȸÀÇ °Ë»ö, °ËÅ並 ´ã´ç(ÀǾàÇ°, ÀÇ·á±â±â, ü¿ÜÁø´Ü¿ë ½Ã¾à ¹× ±â±â µî)
  • cross-functional team°ú ÇÔ²² due diligence¸¦ ÁÖ°üÇÏ¿© Æò°¡¸¦ ÁøÇà
  • Á¦Ç°, ½ÃÀå, finance modelingÀ» Æ÷ÇÔÇÑ »ç¾÷Á¦¾È¼­ °³¹ßÀ» Áö¿ø
  • µµÀÔ °áÁ¤½Ã ¾ç»ç°¡ win-winÇÒ ¼ö ÀÖµµ·Ï Çù»ó ¹× °è¾àÀ» Áö¿ø

Alliance Management
  • ÆÄÆ®³Ê»ç¿ÍÀÇ KPI ´Þ¼º ¹× the day-to-day ¾÷¹«¸¦ ´ã´ç.
  • ¹®Á¦°¡ ¿¹»óµÇ°Å³ª ¹ß»ý½Ã ÇØ°á ¹æ¾ÈÀ» Á¦½ÃÇÏ¸ç °ü·Ã ºÎ¼­ coordination
  • ³»¿ÜºÎ ÆÄÆ®³Ê¿Í Á¤±âÀû ¹ÌÆà µîÀ¸·Î ¿ìÈ£ÀûÀÎ ¾÷¹« ÇùÁ¶ °ü°è Á¶¼º.
Áö¿øÀÚ°Ý
  • ¾àÇÐ, »ý¸í°úÇÐ, »ý¹°ÇÐ, ÀÇ°øÇÐ °ü·Ã Àü°ø Çлç ÀÌ»ó, ¼®¹Ú»ç ¿ì´ë
  • °ü·Ã ¾÷¹« 3³â ÀÌ»óÀÎÀÚ·Î ¶óÀ̼¾½Ì/°³¹ß/BD ¾÷¹« 1³â ÀÌ»ó Çʼö
  • ÇコÄÉ¾î »ê¾÷¿¡ ´ëÇÑ ÀÌÇØ
  • LI/LOÀ» ÁøÇà °¡´ÉÇÑ Á¤µµÀÇ scientific, technical, business and financial Áö½Ä
  • ´Ù¾çÇÑ stakeholder¿Í Çù¾÷ÇÏ´Â ´É·Â
  • ¿ì¼öÇÑ ¼­¸é&±¸µÎ communication skill
  • »ç¾÷ ³íÀÇ°¡ °¡´ÉÇÒ Á¤µµÀÇ ¿Ü±¹¾î ´É·Â
  • Ã¥ÀÓ°¨ ÀÖ°í Àû±ØÀûÀÎ ¾÷¹« ŵµ
[Çѵ¶Á¦¼®Àç´Ü] Àç´Ü¿î¿µ ¹× Àü½Ã±âȹ ´ã´çÀÚ
°ø°í¸¶°¨ÀÏ
  • 2024/05/06
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼ ºñ¿µ¸® °øÀ͹ýÀÎÀÎ Çѵ¶Á¦¼®Àç´ÜÀº (ÁÖ)Çѵ¶°ú â¾÷ÁÖ Íº ±è½Å±Ç ȸÀå´ÔÀÇ ±âºÎ¸¦ ¹ÙÅÁÀ¸·Î ±â¾÷ÀÇ »çȸÀû Ã¥ÀÓÀ» ´ÙÇϱâ À§ÇØ 2006³â 3¿ù Ãâ¹üÇÏ¿´½À´Ï´Ù.
1964³â °³°üÇÑ Çѵ¶ÀǾà¹Ú¹°°üÀ» ÆíÀÔÇÏ¿© ÀǾàÇÐ ºÐ¾ßÀÇ ¿ª»ç¸¦ ¾Ë¸®±â À§ÇÑ Çѵ¶ÀǾà¹Ú¹°°ü ¿î¿µ, ÀǾàÇÐ ºÐ¾ß ÀåÇÐ ¹× ¿¬±¸ Áö¿ø, Áúº´ÅðÄ¡ ¹× ¼Ò¿Ü°èÃþ Áö¿ø»ç¾÷ µî ´Ù¾çÇÑ °øÀÍ»ç¾÷À» ÆîÄ¡°í ÀÖ½À´Ï´Ù.
  • °øÀ͹ýÀÎ ¿î¿µ °ü·Ã ¾÷¹«(¿¹»ê Æí¼º ¹× ÁýÇà, ±âºÎ±Ý °ü¸®, Àç´Ü ÀÌ»çȸ ¿î¿µ µî)
  • ¹Ú¹°°ü ¿î¿µ °ü·Ã ¾÷¹«(±âȹ, È«º¸, ±¹°íÁö¿ø»ç¾÷, ´º½º·¹ÅÍ ¹ßÇà µî)
  • Àü½Ã¡¤°ø¿¬±âȹ(Çö´ë ¹Ì¼ú ±âȹÀü½Ã, ¸Þ¼¼³ª ¿¬°è ¹Ì´Ï Äܼ­Æ®)
  • ÀǾà´ë ÀåÇлý¡¤ÀǾàÇÐ ¿¬±¸Áö¿ø »ç¾÷ ¿î¿µ
  • Çѵ¶ ±â¾÷»çȸ°øÇåÆÀ°úÀÇ Çù¾÷(Çѵ¶ÀÓÁ÷¿ø ºÀ»ç´Ü HiºÀ»ç´Ü ¿î¿µ)
  • ¹Ú¹°°ü ¿Ü Àç´ÜÀÇ °íÀ¯¸ñÀû»ç¾÷ ÁøÇà
Áö¿øÀÚ°Ý
  • Àç´Ü¹ýÀÎ ±Ù¹«°æ·Â ÀÖ´Â ºÐ (5³â ÀÌ»ó)
  • ¹Ú¹°°ü/¹Ì¼ú°ü °ü·Ã ¾÷¹« À¯°æÇèÀÚ ¿ì´ë
  • Àü½Ã¡¤°ø¿¬±âȹ ¿î¿µ À¯°æÇèÀÚ ¿ì´ë
  • ¿îÀü°¡´ÉÀÚ ¿ì´ë
  • ÃÖ±Ù 2³â À̳»ÀÇ ÅäÀÍ µî À¯È¿ÇÑ °øÀξîÇмºÀû º¸À¯ÀÚ
Medical Information °æ·Â ä¿ë
°ø°í¸¶°¨ÀÏ
  • 2024/05/06
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • ½ÅÀÔ/°æ·Â
Á÷¹«»ó¼¼ Medical Information Service(MIS): ³»ºÎ ¹× ¿ÜºÎÀÇ Á¦Ç° °ü·Ã ȤÀº ÀÇÇÐÀû ¹®ÀÇ(Medical Inquiry)¿¡ ºü¸£°í, Á¤È®Çϸç, °´°üÀû Á¤º¸¸¦ Á¦°ø
  • Á¤ÇØÁø timeline ³»¿¡ ±Ù°Å Áß½ÉÀÇ Á¤È®ÇÏ°í °´°üÀûÀÎ ´äº¯ ÀÛ¼º ¹× Á¦°ø
  • Medical inquiry log ¹× ´äº¯¼­ DB °ü¸® (MIMS, Medical Inquiry Management System ÀÌ¿ë)

Promotional Material Review: Çѵ¶¿¡¼­ Á¦ÀÛÇÏ´Â Á¦Ç°/Áúȯ °ü·Ã ±¤°í¼±Àü¹° ¹× È«º¸ÀÚ·á, ¿¬ÀÚ ¹ßÇ¥ ÀÚ·áÀÇ °ËÅä ¹× °ü¸®
  • ±¤°í¼±Àü¹° °ü·Ã ±ÔÁ¤(SOP, ¾à»ç¹ý, ÀÇ·á±â±â¹ý, ½ÄÇ°À§»ý¹ý µî)¿¡ ±Ù°ÅÇÏ¿© °ËÅä: 1Â÷ °ËÅäÀÚ
  • ±ÔÁ¤¿¡ µû¸¥ ±¤°í¼±Àü È°µ¿ ¹× ±¤°í¼±Àü¹° Á¦ÀÛ/»ç¿ë/Æó±â/¾÷µ¥ÀÌÆ®¸¦ À¯µµÇϱâ À§ÇØ °ü·Ã ºÎ¼­¿Í Çù¾÷
  • ±¤°í¼±Àü¹° °ËÅä ¹®¼­ ¹× ½Ç¹° archiving

Medical News Service: ³»ºÎ Á÷¿ø(¿¬±¸°³¹ßº»ºÎ,¸¶ÄÉÆÃ, ¿µ¾÷ µî)¿¡°Ô ±¹³»¿Ü ¾÷°è ¿¬±¸°³¹ß µ¿Çâ ¹× ÃֽŠÀǾàÇÐ Á¤º¸(´º½º,³í¹® µî)¸¦ Á¦°øÇÏ¿© ¾÷¹« Çâ»óÀ» µ½´Â´Ù.
Cooperation: Ÿ ºÎ¼­¿Í ¾÷¹« ÇùÁ¶
  • RA½Ç: Label¿¡ ´ëÇÑ ÀÇÇÐÀû °ËÅä: 1Â÷ °ËÅäÀÚ
  • SCM: Æ÷Àå¹° ¹× Á¦Ç°¼³¸í¼­ ³» ±¤°í¼±Àü ¹®±¸ °ËÅä: 1Â÷ °ËÅäÀÚ
  • PV: PV SOP¸¦ Áؼö, ÀÚ¹ßÀû ÀÌ»ó¹ÝÀÀ º¸°í Àü´Þ

Knowledge management: Á¶Á÷ ³» Áö½Ä ÀüÆÄ ¹× ÃàÀû¸¦ À§ÇØ Á¦Ç°/Áúȯ, ¾÷¹« °ü·Ã Áö½Ä ¹× know-how¸¦ ¹®¼­È­ÇÏ°í °øÀ¯ÇÑ´Ù.
Áö¿øÀÚ°Ý
  • ¾àÇдëÇÐ, ÀÇ°ú´ëÇÐ, °£È£´ëÇÐ µî Àü°øÀÚ·Î Çлç ÇÐÀ§ ÀÌ»ó
  • Á¦¾àȸ»ç MI ¹× º´¿ø µî °ü·Ã °æ·Â 1³â ÀÌ»ó º¸À¯ÇϽŠºÐ ¼±È£
  • ÀǾàÇ°/Áúȯ, ÀÇÇÐ ¿¬±¸ ¹× ¾÷¹« °ü·Ã ±ÔÁ¤¿¡ ´ëÇÑ Áö½Ä
  • Àû±ØÀûÀÌ°í ÇùÁ¶ÀûÀÌ¸ç ¿ø¸¸ÇÑ ´ëÀΰü°è ¼ÒÀ¯ÀÚ
  • °í°´ ÀÀ´ë¿¡¼­ ¹«¸® ¾ø´Â ÀÇ»çÀü´Þ°ú Ç¥Çö´É·ÂÀÌ ÀÖÀ¸½Å ºÐ
  • ¿µ¹®¼­ ¹ø¿ª ¹× ÀÛ¼º¿¡ ¾î·Á¿òÀÌ ¾ø°í ÀǾàÇÐ Çмú ¹®Çå ÀÌÇØ¿¡ ¾î·Á¿òÀÌ ¾ø´Â ºÐ
  • MS Office ¹× Á¤º¸ °Ë»ö toolÀ» ¿øÈ°ÇÏ°Ô È°¿ëÇÒ ¼ö ÀÖ´Â ºÐ
  • ÀǾàÇ° ¿¬±¸ ¹× °³¹ß °úÁ¤ Àü¹Ý¿¡ ´ëÇÑ ÀÌÇØ.
  • ´Éµ¿Àû ±³À° Âü¿©¸¦ ÅëÇÑ Áö¼ÓÀûÀÎ Àڱ⠰³¹ß
¸¸¼ºÁúȯ ´ç´¢/¼øȯ±â Marketing
°ø°í¸¶°¨ÀÏ
  • ä¿ë ½Ã±îÁö ¸ðÁý
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
  • ¿µ¾÷Á÷ÀÇ °æ¿ì, º»ÀÎÀÇ ´ã´ç È°µ¿ Áö¿ª
°æ·Â±¸ºÐ
  • ½ÅÀÔ/°æ·Â
Á÷¹«»ó¼¼ Àü¹®ÀǾàÇ° ´ç´¢ ¹× ¼øȯ±â ¿µ¿ªÀÇ Á¦Ç°À» ´ã´çÇÏ´Â ETC DCV Marketing
  1. Marketing planning & implementation
    • Resource allocation: Products mix against targets, A&P allocation efficiency
    • Long-term franchise strategy and planning: portfolio growth, alliance/business partnership
    • Timely report the supervisor according to objectives mutually agreed upon from year-to-year.
    • Take a ownership of specific brand performance measures
    • Perform developmental project base such as secondary market research, data analysis and etc.
    • Conduct a variety of administrative functions such as medical legal mark-ups, material development, clinical study utilization & field force communication, all essential to the day to day operation of the brand
  2. Key customer management :
    • Regular visit to target physicians
    • Provide physicians with updated highly scientific information on product & disease
    • Shape physicians' view on the disease and establish need for product
  3. Scientific program support
    • Develop key speakers to become strong advocates for the product & therapeutic class
    • Lead scientific initiatives to build clinical evident and implement medical programs
    • Search & provide updated articles on the product and develop key message
    • Deliver MR product training
  4. People, Capabilities, and Management:
    • Talent acquisition
    • Responsible for compliance with all legal requirements of company policies and ensure strict compliance
Áö¿øÀÚ°Ý
  • 2~3 years of sales & 3~5 marketing experience : Must (5³â ÀÌ»ó Sales & MKTing °æ·Â)
  • Commercial experience of Diabetes mellitus / Cardiovascular field in pharmaceutical firm : preferred
  • Intermediate English communication/Presentation skill
  • High level communication skills
  • Proven project management skill (in the planning and new business case) : Understanding of P&L analysis
  • Creative and innovative approaches to problem solving
  • Strategic orientation
  • Pro-activity and willingness to initiative
  • Ability to foster and manage productive biz relationship with external stakeholders
Life Science½Ç Marketing
°ø°í¸¶°¨ÀÏ
  • ä¿ë½Ã±îÁö ¸ðÁý (1Â÷ ¼­·ù¸¶°¨ 2024/04/10)
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼
  • ºê·£µå»ç (QIAGEN/ EPPENDORF/ Cellsafe/ Advanced Instrument) PO °ü¸®, ¸¶ÄÉÆà Àü·« ¼ö¸³, È«º¸ È°µ¿, Á¦Ç°±³À°
  • ºê·£µå»ç ¹× ¿µ¾÷»ç¿ø, ³»ºÎ À¯°üºÎ¼­¿ÍÀÇ ¿øÈ°ÇÑ Communication
  • ¸¶ÄÉÆà ¿¹»ê Planning, ÁýÇà ¹× °ü¸®
  • ½ÃÀå µ¿Çâ ¹× °æÀï»ç Á¤º¸¸¦ ÅëÇÑ ¸¶ÄÏ ºÐ¼®
  • ½Å±Ô ºê·£µå °³¹ß
Áö¿øÀÚ°Ý
  • 4³âÁ¦ ´ëÇÐ ÀÌ»ó (»ý¸í°øÇÐ, »ý¹°ÇÐ, ÀÇ»ý¸í°úÇаú µî °ü·Ã Àü°ø ¹× °ü·Ã ¼®»ç ¿ì´ë)
  • µ¿Á¾ ¾÷°è 4³â ÀÌ»ó °æ·Â º¸À¯ÀÚ
  • ¿Ü±¹°è ÆÄÆ®³Ê»ç¿Í ±âº»ÀûÀÎ ¿µ¾î ÀÇ»ç¼ÒÅë °¡´ÉÀÚ (¿µ¾î Speaking Test ÁøÇà)
  • ¿îÀü¸éÇã ÀÚ°ÝÁõ º¸À¯ÀÚ (2Á¾ º¸Åë ÀÌ»ó)
Life Science Çмú¿µ¾÷ (°æ·Â)
°ø°í¸¶°¨ÀÏ
  • 2024/04/28
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼ Life Science Çмú¿µ¾÷
  • ºê·£µå»ç (QIAGEN/ Cellsafe/ New business)ÀÇ ¿¬±¸½Ã¾à ¹× Àåºñ¿¡ ´ëÇÑ °í°´ ±â¼ú Á¤º¸ ¼¼¹Ì³ª ¹× »ó´ã
  • Applicationº° Á¦Ç° Æ÷Æ®Æú¸®¿À Â÷º°È­¸¦ ÅëÇÑ Çмú¿µ¾÷Àü·« ¼ö¸³
  • ´ë¸®Á¡ ¹× ¿µ¾÷»ç¿ø ±³À°
  • ½ÅÁ¦Ç° ¹× Á¦Ç° Á¤º¸ ºÐ¼® ¹× ¸ÅÃ⠺м®
  • ½ÃÀå µ¿Çâ ¹× °æÀï»ç Á¤º¸ ȹµæ ¹× º¸°í
Áö¿øÀÚ°Ý
  • 4³âÁ¦ ´ëÇÐ ÀÌ»ó (»ý¸í°øÇÐ, »ý¹°ÇÐ, ÀÇ»ý¸í°úÇаú µî °ü·Ã Àü°ø ¹× °ü·Ã ¼®»ç ¿ì´ë)
  • ÀÇ·á±â±â ¾÷°è °æ·Â 3³â ÀÌ»ó
  • ¿µ¾î Áß±Þ µ¿µî/ÀÌ»ó (Á¦Ç°±³À° ½Ã, ¿µ¾î·Î ÁøÇà °¡´É¼º)
  • ¿îÀü¸éÇã ÀÚ°ÝÁõÀÌ ÀÖÀ¸½Å ºÐ (2Á¾ º¸Åë ÀÌ»ó)
    • °øÀξîÇмºÀûÀÌ ¾øÀ¸½Å °æ¿ì, ÀÚ»ç ÁÖ°üÀÇ ¸ðÀÇ ÅäÀÍÀ» ½Ç½ÃÇÒ ¿¹Á¤ÀÔ´Ï´Ù.
[°è¾àÁ÷] HSE Ãѹ«ÆÀ¿ø ä¿ë
°ø°í¸¶°¨ÀÏ
  • 2024/04/28 (¿¬Àå)
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • ½ÅÀÔ ¹× °æ·Â
Á÷¹«»ó¼¼
  • »ç³» Çà»ç¿î¿µ Áغñ ¹× Áö¿ø
  • »ç³» ÀÚ»ê°ü¸® ¾÷¹« Áö¿ø
  • ÀÓÁ÷¿ø ºñÇ° ¹× Àμ⹰ °ü¸®
  • ±¸³»½Ä´ç ¹× Ä«Æä °ü·Ã »ç¹« º¸Á¶
Áö¿øÀÚ°Ý
  • 4³âÁ¦ ´ëÁ¹ ÀÌ»ó
  • ½ÅÀÔ ¹× °æ·Â
  • ¹®¼­ ÀÛ¾÷(MS Office) ¼÷·ÃÀÚ ¿ì´ë
  • ¹®Á¦ÇذῪ·®, Communication ¿ª·®
  • ÁÖµµÀû Çൿ, ±àÁ¤Àû ŵµ
[À°¾ÆÈÞÁ÷ ´ëü °è¾àÁ÷] Clinical Quality associate ¸ðÁý
°ø°í¸¶°¨ÀÏ
  • 2024/05/06 (¿¬Àå)
±Ù¹«Áö
  • Çѵ¶ º»»ç (¼­¿ï½Ã °­³²±¸ Å×Çì¶õ·Î 132)
°æ·Â±¸ºÐ
  • °æ·Â
Á÷¹«»ó¼¼
  • »ç³» ÀÓ»ó½ÃÇè Á¾»çÀÚÀÇ ±³À° ½ÇÀû È®ÀÎ ¹× °ü¸®
  • ½Å±Ô Á÷¿øÀÇ OJT curriculum Áغñ ¹× °ü¸®
  • Á÷¿ø ±³À° ±â·ÏÀÇ °ü¸®, ³»/¿ÜºÎ ±³À° ÀÏÁ¤ °ü¸®
  • GCP/GVP °ü·Ã ¾÷¹« À§Å¹ ¾÷ü¿¡ ´ëÇÑ qualification Æò°¡ ¼öÇà ¶Ç´Â °ü¸® Áö¿ø
  • External partner audit ¹× º¸°Ç ´ç±¹ÀÇ inspection Áغñ
  • P&P/SOP, °ü·Ã ±ÔÁ¤, °èȹ¼­ À§¹Ý µî Monitor, CAPA ½ÇÇà follow-up
  • °ü·Ã ¹ý±Ô ¹× ȸ»ç policy¸¦ ÁؼöÇÏ´Â draft P&P ¹×/¶Ç´Â SOP °ü¸®
  • °ü·Ã ¹ý±Ô Á¦¡¤°³Á¤ ½Ã À¯°ü ºÎ¼­ÀÇ ¹ý±Ô ¿µÇâ Æò°¡ ÀýÂ÷ coordinating ¹× follow-up
Áö¿øÀÚ°Ý
  • ÀÇÇÐ, °£È£ÇÐ, ¾àÇÐ, ¼öÀÇÇÐ, º¸°ÇÇÐ µî »ý¸í°úÇÐ °ü·Ã 4³âÁ¦ ÀÌ»ó ´ëÇÐ Á¹¾÷
  • ÀÓ»ó½ÃÇè °ü·Ã ¾÷¹« ¶Ç´Â QA ¾÷¹« °æ·Â º¸À¯ÀÚ
  • GCP/GVP ±ÔÁ¤¿¡ ´ëÇÑ Àü¹® Áö½Ä ¹× ÀÌÇØ, ±âŸ ÀÇÇÐ ¿ë¾î ¹× ÀǾ࿡ °üÇÑ Áö½Ä ¹× ÀÌÇØ
  • ÁÁÀº ´ëÀÎ °ü°è, Ã¥ÀÓ°¨, ´Éµ¿ÀûÀÎ ¾÷¹« ó¸® ´É·Â, Time Management
  • °Ç°­ÇÔ, Àγ»½É, Good mind-control, ¼¼¹ÐÇÔ, ÀÚ±â°è¹ß¿¡ Àû±ØÀûÀΠŵµ µî

ÀüÇü´Ü°è


Á¦Ãâ¼­·ù

  • ÃÖÁ¾ÇÕ°Ý ÈÄ Á¦Ãâ